Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 799Precursor Cell Lymphoblastic Leukemia-Lymphoma 169Recurrence 140Neoplasms, Plasma Cell 110Lymphoma 93Leukemia 91Neoplasms 81Burkitt Lymphoma 57Vomiting 51Lymphoma, Non-Hodgkin 50Immunoglobulin Light-chain Amyloidosis 49Lymphoma, Large B-Cell, Diffuse 44Nausea 38Lymphoma, Mantle-Cell 38Prostatic Neoplasms 31Lymphoma, Follicular 30Hodgkin Disease 29Waldenstrom Macroglobulinemia 27Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 27Neoplasm Metastasis 26Leukemia, Lymphocytic, Chronic, B-Cell 26Carcinoma, Non-Small-Cell Lung 26Leukemia, Myeloid, Acute 25Breast Neoplasms 25Lung Neoplasms 22Amyloidosis 21Leukemia, Biphenotypic, Acute 18Lymphoma, B-Cell, Marginal Zone 17Lymphoma, Extranodal NK-T-Cell 16Smoldering Multiple Myeloma 15

Interventions

3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol 6TH 302 4Radiotherapy 4pimonidazole 3fluoroazomycin arabinoside 3Propofol 3Injections 3Positron Emission Tomography Computed Tomography 2Blood Specimen Collection 2Bacterial Load 2pomalidomide 1pembrolizumab 1inositol trispyrophosphate 1gadobutrol 1fluoromisonidazole 1fludarabine 1Tirapazamine 1Temozolomide 1Sodium Chloride 1Sevoflurane 1Saline Solution 1Pancreaticoduodenectomy 1Paclitaxel 1Oxygen 1Nitroglycerin 1Nimorazole 1NVP-BKM120 1Metformin 1Magnetic Resonance Spectroscopy 1Ketamine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hypoxia × Dexamethasone × Clear all
NCT01522872 2016-06-02

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

Threshold Pharmaceuticals

Phase 1/2 Unknown
98 enrolled
Plasma cell

Hypoxia, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡